Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 621


Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A.

Biol Blood Marrow Transplant. 2005 May;11(5):389-98.


Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.

Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, et al.

J Clin Oncol. 1994 Jan;12(1):28-36.


Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.

Engelhardt M, Douville J, Behringer D, Jähne A, Smith A, Henschler R, Lange W.

Bone Marrow Transplant. 2001 Feb;27(3):249-59.


Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.

Williams SF, Lee WJ, Bender JG, Zimmerman T, Swinney P, Blake M, Carreon J, Schilling M, Smith S, Williams DE, Oldham F, Van Epps D.

Blood. 1996 Mar 1;87(5):1687-91.


Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer.

McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ.

Blood. 2000 Nov 1;96(9):3001-7.


A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy.

Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R.

Blood. 1997 Dec 1;90(11):4313-20.


Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?

Ener RA, Meglathery SB, Cuhaci B, Topolsky D, Styler MJ, Crilley P, Brodsky I, Kahn SB, King RS.

Am J Clin Oncol. 2001 Feb;24(1):19-25.


Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.

Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, et al.

J Clin Oncol. 1994 Jan;12(1):37-44.


Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.

Zimmerman TM, Lee WJ, Bender JG, Schilling M, Smith SL, Van Epps DE, Williams SF.

Bone Marrow Transplant. 2000 Sep;26(5):505-10.


Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery.

Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA.

Exp Hematol. 2002 Apr;30(4):374-80.


Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.

Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F.

Bone Marrow Transplant. 1999 Nov;24(9):971-9.


Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer.

Stiff P, Chen B, Franklin W, Oldenberg D, Hsi E, Bayer R, Shpall E, Douville J, Mandalam R, Malhotra D, Muller T, Armstrong RD, Smith A.

Blood. 2000 Mar 15;95(6):2169-74.


GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.

Elias AD, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Pelaez J, Hunt M, et al.

Breast Cancer Res Treat. 1991 Dec;20 Suppl:S25-9.


Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.

Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS.

Exp Hematol. 2000 Jan;28(1):96-103. Erratum in: Exp Hematol. 2000 Mar;28(3):347.


Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer.

McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ.

Hematol Cell Ther. 1999 Apr;41(2):82-6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk